Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 sept. 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
30 août 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
15 août 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit

Data demonstrates continued efficacy of marzeptacog alfa (activated) in two additional subjects SOUTH SAN FRANCISCO, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc....
13 août 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
02 août 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Update

Announced Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) in Individuals with Hemophilia A or B with Inhibitors Presented CB 2679d (FIX) Phase 1/2...
18 juil. 2018 07h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors

Interim data support goal of significantly reducing annualized bleed rates with daily subcutaneous injections of marzeptacog alfa (activated) Conference call and webcast to be held today, July 18,...
12 juil. 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis

Conference call and webcast to be held Wednesday, July 18, 2018 at 8:30 a.m. EDT SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a...
10 juil. 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research

SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
25 juin 2018 08h30 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Joins the Russell 2000® Index

SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
19 juin 2018 08h00 HE | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the JMP Securities 2018 Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...

Page précédente